The present invention relates to novel glucocorticoid compounds. The invention also relates to methods of using these compounds, the synthesis of these compounds, and to compositions and formulations comprising the glucocorticoid compounds, and uses thereof.

The invention provides gastric residence systems with specifically tailored architectures and methods for making such systems. The components of the gastric residence systems can be manufactured by three-dimensional printing or by co-extrusion. The ability to construct precise architectures for the systems provides excellent control over drug release, in vivo stability, and residence time of the systems.

Provided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

The invention relates to a pharmaceutical composition comprising an isotonic aqueous solution comprising from about 0.05 g/mL to about 10 mg/mL of a compound of formula I: ##STR00001##
or a pharmaceutically acceptable salt thereof.

Provided herein are methods for prophylactic treatment of renal disorders comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual suspected of having, predisposed to, or at risk of developing a renal disorder.

The present invention provides compositions for delivering an active agent to an animal, comprising an active agent, a first coating, a second coating and a third coating. The active agent is coated with the first coating, the first coating is coated with the second coating, and the second coating is coated with the third coating. The active agent is in contact with the first coating, not the second or third coating. The first coating separates the active agent from the second coating while the second coating separates the first and third coatings. The first, second and third coatings are different from each other. Also provided are methods for making and using the compositions.

Topical compositions comprising a corticosteroid, at least one alcohol, and a penetration enhancing agent.

The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).

The present invention relates to methods of treating mast cell tumors and soft tissue sarcomas using 6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one derivatives in combination with at least one other pharmaceutically active agent. In particular embodiments, the tigliaen-3-one derivatives are 12, 13-acyl or ether derivatives and the derivative compound is delivered in a localised manner to the tumor or sarcoma. In particular embodiments, the at least one other pharmaceutically active agent is selected from an antihistamine, an anti-inflammatory agent and mixtures thereof.

Disclosed herein are recombinant adeno-associated viral vectors expressing 21-hydroxy lase (21OH) protein and related uses for treating 21OH deficiency.